Ischemic Cardiomyopathy
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Ischemic Cardiomyopathy is an emerging landscape with 17 programs across 11 companies. The most active players are Jiangsu Topcel-KH Pharmaceutical Co., Ltd., Nobelpharma, Sinotau Pharmaceutical Group. 4 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
1 program
Nobelpharma
1 program
Sinotau Pharmaceutical Group
2 programs
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
1 program
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 program
Val Adams
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
81%
Small molecule
17 of 21 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 96% of 28 pipeline programs.
Analysis
Trial Status
29
clinical trials
Clinical Trials
Trial Activity
29 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)